{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:48:14Z","timestamp":1782416894989,"version":"3.54.5"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1 AG079519"],"award-info":[{"award-number":["RF1 AG079519"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1 AG079519"],"award-info":[{"award-number":["RF1 AG079519"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1 AG079519"],"award-info":[{"award-number":["RF1 AG079519"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AG051412"],"award-info":[{"award-number":["U01 AG051412"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG068054"],"award-info":[{"award-number":["U19 AG068054"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG068054"],"award-info":[{"award-number":["U19 AG068054"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG068054"],"award-info":[{"award-number":["U19 AG068054"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG068054"],"award-info":[{"award-number":["U19 AG068054"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG068054"],"award-info":[{"award-number":["U19 AG068054"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG068054"],"award-info":[{"award-number":["U19 AG068054"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG068054"],"award-info":[{"award-number":["U19 AG068054"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG068054"],"award-info":[{"award-number":["U19 AG068054"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG068054"],"award-info":[{"award-number":["U19 AG068054"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1 AG079519"],"award-info":[{"award-number":["RF1 AG079519"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1 AG079519"],"award-info":[{"award-number":["RF1 AG079519"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1 AG079519"],"award-info":[{"award-number":["RF1 AG079519"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adults with Down syndrome have a genetic form of Alzheimer\u2019s disease (AD) and evidence of cerebrovascular disease across the AD continuum, despite few systemic vascular risk factors. The onset and progression of AD in Down syndrome is highly age-dependent, but it is unknown at what age cerebrovascular disease emerges and what factors influence its severity. In the Alzheimer\u2019s Biomarker Consortium-Down Syndrome study (ABC-DS; n\u2009=\u2009242; age\u2009=\u200925\u201372), we estimated the age inflection point at which MRI-based white matter hyperintensities (WMH), enlarged perivascular spaces (PVS), microbleeds, and infarcts emerge in relation to demographic data, risk factors, amyloid and tau, and AD diagnosis. Enlarged PVS and infarcts appear to develop in the early 30s, while microbleeds, WMH, amyloid, and tau emerge in the mid to late 30s. Age-residualized WMH were higher in women, in individuals with dementia, and with lower body mass index. Participants with hypertension and APOE-\u03b54 had higher age-residualized PVS and microbleeds, respectively. Lifespan trajectories demonstrate a dramatic cerebrovascular profile in adults with Down syndrome that appears to evolve developmentally in parallel with AD pathophysiology approximately two decades prior to dementia symptoms.<\/jats:p>","DOI":"10.1038\/s41598-024-61962-y","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T12:02:03Z","timestamp":1716984123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cerebrovascular disease emerges with age and Alzheimer\u2019s disease in adults with Down syndrome"],"prefix":"10.1038","volume":"14","author":[{"given":"Patrick","family":"Lao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisi","family":"Flores-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Alshikho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batool","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Tudorascu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Diana","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Yassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley T.","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mapstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Handen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly E.","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Wilcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Head","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Brickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"61962_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1176\/ajp.105.2.102","volume":"105","author":"GA Jervis","year":"1948","unstructured":"Jervis, G. A. Early senile dementia in mongoloid idiocy. Am. J. Psychiatry 105, 102\u2013106 (1948).","journal-title":"Am. J. Psychiatry"},{"key":"61962_CR2","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/0006-291X(84)91209-9","volume":"122","author":"GG Glenner","year":"1984","unstructured":"Glenner, G. G., Wong, C. W., J. B. & communications. Alzheimer\u2019s disease and Down\u2019s syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122, 1131\u20131135 (1984).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"61962_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1750-3639.1991.tb00667.x","volume":"1","author":"K Beyreuther","year":"1991","unstructured":"Beyreuther, K. & Masters, C. L. Amyloid precursor protein (APP) and \u0392ZA4 amyloid in the etiology of Alzheimer\u2019s disease: Precursor-product relationships in the derangement of neuronal function. Brain Pathol. 1, 241\u2013251 (1991).","journal-title":"Brain Pathol."},{"key":"61962_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy, J. & Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol. Sci. 12, 383\u2013388 (1991).","journal-title":"Trends Pharmacol. Sci."},{"key":"61962_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe, D. J. The molecular pathology of Alzheimer\u2019s disease. Neuron 6, 487\u2013498 (1991).","journal-title":"Neuron"},{"key":"61962_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy, J. A. & Higgins, G. A. J. S. Alzheimer\u2019s disease: The amyloid cascade hypothesis. Science 256, 184\u2013185 (1992).","journal-title":"Science"},{"issue":"1062","key":"61962_CR7","first-page":"1066","volume":"62","author":"F Oyama","year":"1994","unstructured":"Oyama, F. et al. Down\u2019s syndrome: Up-regulation of \u03b2-amyloid protein precursor and \u03c4 mRNAs and their defective coordination. J. Neurochem. 62(1062), 1066 (1994).","journal-title":"J. Neurochem."},{"key":"61962_CR8","first-page":"e12062","volume":"12","author":"MS Rafii","year":"2020","unstructured":"Rafii, M. S. et al. The AT (N) framework for Alzheimer\u2019s disease in adults with Down syndrome. Alzheimer\u2019s Dement.: Diagn. Assess. Dis. Monit. 12, e12062 (2020).","journal-title":"Alzheimer's Dement.: Diagn. Assess. Dis. Monit."},{"issue":"1","key":"61962_CR9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/alz.13446","volume":"20","author":"SL Hartley","year":"2023","unstructured":"Hartley, S. L. et al. AT (N) biomarker profiles and Alzheimer\u2019s disease symptomology in Down syndrome. Alzheimer\u2019s Dement. 20(1), 366\u2013375 (2023).","journal-title":"Alzheimer's Dement."},{"issue":"930","key":"61962_CR10","first-page":"942","volume":"20","author":"J Fortea","year":"2021","unstructured":"Fortea, J. et al. Alzheimer\u2019s disease associated with Down syndrome: A genetic form of dementia. Lancet Neurol. 20(930), 942 (2021).","journal-title":"Lancet Neurol."},{"issue":"55","key":"61962_CR11","first-page":"65","volume":"22","author":"AH Boerwinkle","year":"2023","unstructured":"Boerwinkle, A. H. et al. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer\u2019s disease: A cross-sectional study. Lancet Neurol. 22(55), 65 (2023).","journal-title":"Lancet Neurol."},{"key":"61962_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018 (2018).","journal-title":"Alzheimers Dement."},{"key":"61962_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","volume":"17","author":"H Hampel","year":"2021","unstructured":"Hampel, H. et al. Developing the ATX (N) classification for use across the Alzheimer disease continuum. Nat. Rev. Neurol. 17, 580\u2013589 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"61962_CR14","unstructured":"Workgroup, A. s. A. Revised criteria for diagnosis and staging of Alzheimer's disease. (2023)."},{"key":"61962_CR15","doi-asserted-by":"publisher","first-page":"e2212910","DOI":"10.1001\/jamanetworkopen.2022.12910","volume":"5","author":"MF Iulita","year":"2022","unstructured":"Iulita, M. F. et al. Association of Alzheimer disease with life expectancy in people with Down syndrome. JAMA Netw. Open 5, e2212910\u2013e2212910 (2022).","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"61962_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","volume":"83","author":"JJD Cummings","year":"2023","unstructured":"Cummings, J. J. D. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s disease therapeutics. Drugs 83(7), 569\u2013576 (2023).","journal-title":"Drugs"},{"key":"61962_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston, G. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396, 413\u2013446 (2020).","journal-title":"Lancet"},{"key":"61962_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00401-017-1717-7","volume":"134","author":"A Kapasi","year":"2017","unstructured":"Kapasi, A., DeCarli, C. & Schneider, J. A. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 134, 171\u2013186. https:\/\/doi.org\/10.1007\/s00401-017-1717-7 (2017).","journal-title":"Acta Neuropathol."},{"key":"61962_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1212\/wnl.0000000000001834","volume":"85","author":"LL Barnes","year":"2015","unstructured":"Barnes, L. L. et al. Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology 85, 528\u2013534. https:\/\/doi.org\/10.1212\/wnl.0000000000001834 (2015).","journal-title":"Neurology"},{"key":"61962_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neurobiolaging.2014.07.019","volume":"36","author":"AM Brickman","year":"2015","unstructured":"Brickman, A. M. et al. Reconsidering harbingers of dementia: Progression of parietal lobe white matter hyperintensities predicts Alzheimer\u2019s disease incidence. Neurobiol. Aging 36, 27\u201332 (2015).","journal-title":"Neurobiol. Aging"},{"key":"61962_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.neurobiolaging.2022.05.004","volume":"117","author":"PJ Lao","year":"2022","unstructured":"Lao, P. J. et al. Amyloid, cerebrovascular disease, and neurodegeneration biomarkers are associated with cognitive trajectories in a racially and ethnically diverse, community-based sample. Neurobiol. Aging 117, 83\u201396 (2022).","journal-title":"Neurobiol. Aging"},{"key":"61962_CR22","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/ana.24647","volume":"79","author":"S Lee","year":"2016","unstructured":"Lee, S. et al. White matter hyperintensities are a core feature of Alzheimer\u2019s disease: Evidence from the dominantly inherited Alzheimer network. Ann. Neurol. 79, 929\u2013939. https:\/\/doi.org\/10.1002\/ana.24647 (2016).","journal-title":"Ann. Neurol."},{"key":"61962_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13195-022-01030-7","volume":"14","author":"D Schoemaker","year":"2022","unstructured":"Schoemaker, D. et al. White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer\u2019s disease that emerge prior to dementia. Alzheimer\u2019s Res. Ther. 14, 89 (2022).","journal-title":"Alzheimer's Res. Ther."},{"issue":"2","key":"61962_CR24","doi-asserted-by":"publisher","first-page":"fcaa132","DOI":"10.1093\/braincomms\/fcaa132","volume":"2","author":"KK Laing","year":"2020","unstructured":"Laing, K. K. et al. Cerebrovascular disease promotes tau pathology in Alzheimer\u2019s disease. Brain Commun. 2(2), fcaa132 (2020).","journal-title":"Brain Commun."},{"issue":"885","key":"61962_CR25","first-page":"892","volume":"603","author":"AC Yang","year":"2022","unstructured":"Yang, A. C. et al. A human brain vascular atlas reveals diverse mediators of Alzheimer\u2019s risk. Nature 603(885), 892 (2022).","journal-title":"Nature"},{"key":"61962_CR26","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/ana.25905","volume":"88","author":"PJ Lao","year":"2020","unstructured":"Lao, P. J. et al. Alzheimer-related cerebrovascular disease in Down syndrome. Ann. Neurol. 88, 1165\u20131177 (2020).","journal-title":"Ann. Neurol."},{"issue":"1744","key":"61962_CR27","first-page":"1753","volume":"18","author":"F Moni","year":"2022","unstructured":"Moni, F. et al. Probing the proteome to explore potential correlates of increased Alzheimer\u2019s-related cerebrovascular disease in adults with Down syndrome. Alzheimer\u2019s Dement. 18(1744), 1753 (2022).","journal-title":"Alzheimer's Dement."},{"key":"61962_CR28","doi-asserted-by":"publisher","DOI":"10.1101\/2023.11.28.23298693","author":"NC Edwards","year":"2023","unstructured":"Edwards, N. C. et al. Cerebrovascular disease drives Alzheimer plasma biomarker concentrations in adults with Down syndrome. Medrxiv. https:\/\/doi.org\/10.1101\/2023.11.28.23298693 (2023).","journal-title":"Medrxiv."},{"issue":"723","key":"61962_CR29","first-page":"738","volume":"12","author":"BVJNRN Zlokovic","year":"2011","unstructured":"Zlokovic, B. V. J. N. R. N. Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders. Nat. Rev. Neurosci. 12(723), 738 (2011).","journal-title":"Nat. Rev. Neurosci."},{"issue":"1265","key":"61962_CR30","first-page":"1283","volume":"41","author":"S Scheffer","year":"2021","unstructured":"Scheffer, S. et al. Vascular hypothesis of Alzheimer disease: Topical review of mouse models. Arterioscler. Thromb. Vasc. Biol. 41(1265), 1283 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1581","key":"61962_CR31","first-page":"1597","volume":"63","author":"K Gouveia-Freitas","year":"2021","unstructured":"Gouveia-Freitas, K. & Bastos-Leite, A. J. J. N. Perivascular spaces and brain waste clearance systems: Relevance for neurodegenerative and cerebrovascular pathology. Neuroradiology 63(1581), 1597 (2021).","journal-title":"Neuroradiology"},{"key":"61962_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/strokeaha.114.007568","volume":"46","author":"JW van Dalen","year":"2015","unstructured":"van Dalen, J. W. et al. Cortical microinfarcts detected in vivo on 3 Tesla MRI: Clinical and radiological correlates. Stroke 46, 255\u2013257. https:\/\/doi.org\/10.1161\/strokeaha.114.007568 (2015).","journal-title":"Stroke"},{"key":"61962_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nrneurol.2015.10","volume":"11","author":"ND Prins","year":"2015","unstructured":"Prins, N. D. & Scheltens, P. White matter hyperintensities, cognitive impairment and dementia: An update. Nat. Rev. Neurol. 11, 157\u2013165 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"61962_CR34","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa022066","volume":"348","author":"SE Vermeer","year":"2003","unstructured":"Vermeer, S. E. et al. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. 348, 1215\u20131222 (2003).","journal-title":"N. Engl. J. Med."},{"key":"61962_CR35","doi-asserted-by":"publisher","first-page":"102740","DOI":"10.1016\/j.nicl.2021.102740","volume":"31","author":"MD Zammit","year":"2021","unstructured":"Zammit, M. D. et al. Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in Down syndrome. NeuroImage Clin. 31, 102740 (2021).","journal-title":"NeuroImage Clin."},{"issue":"1","key":"61962_CR36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/alz.13444","volume":"20","author":"MD Zammit","year":"2023","unstructured":"Zammit, M. D. et al. Characterizing the emergence of amyloid and tau burden in Down syndrome. Alzheimer\u2019s Dement. 20(1), 388\u2013398 (2023).","journal-title":"Alzheimer's Dement."},{"key":"61962_CR37","doi-asserted-by":"publisher","first-page":"e12096","DOI":"10.1002\/trc2.12096","volume":"6","author":"D Tudorascu","year":"2020","unstructured":"Tudorascu, D. et al. Relationship of amyloid beta and neurofibrillary tau deposition in Neurodegeneration in Aging Down Syndrome (NiAD) study at baseline. Transl. Res. Clin. Interv. 6, e12096 (2020).","journal-title":"Transl. Res. Clin. Interv."},{"issue":"3","key":"61962_CR38","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/alz.13494","volume":"20","author":"SK Royse","year":"2023","unstructured":"Royse, S. K. et al. Unhealthy white matter connectivity, cognition, and racialization in older adults. Alzheimer\u2019s Dement. 20(3), 1483\u20131496 (2023).","journal-title":"Alzheimer's Dement."},{"issue":"1","key":"61962_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40478-017-0499-4","volume":"5","author":"E Head","year":"2017","unstructured":"Head, E. et al. Cerebrovascular pathology in Down syndrome and Alzheimer disease. Acta Neuropathol. Commun. 5(1), 9 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"61962_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/01.wnl.0000438225.02729.04","volume":"82","author":"A Charidimou","year":"2014","unstructured":"Charidimou, A. et al. White matter perivascular spaces: An MRI marker in pathology-proven cerebral amyloid angiopathy?. Neurology 82, 57\u201362 (2014).","journal-title":"Neurology"},{"key":"61962_CR41","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.3390\/jcm10132966","volume":"10","author":"PG Mhatre","year":"2021","unstructured":"Mhatre, P. G. et al. The association between sex and risk of Alzheimer\u2019s disease in adults with Down syndrome. J. Clin. Med. 10, 2966 (2021).","journal-title":"J. Clin. Med."},{"key":"61962_CR42","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/ana.410400518","volume":"40","author":"N Schupf","year":"1996","unstructured":"Schupf, N. et al. Onset of dementia is associated with apolipoprotein E \u03b54 in Down\u2019s syndrome. Ann. Neurol.: Off. J. Am. Neurol. Assoc. Child Neurol. Soc. 40, 799\u2013801 (1996).","journal-title":"Ann. Neurol.: Off. J. Am. Neurol. Assoc. Child Neurol. Soc."},{"issue":"3","key":"61962_CR43","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3233\/JAD-220865","volume":"91","author":"V Fleming","year":"2023","unstructured":"Fleming, V. et al. Weight loss and Alzheimer\u2019s disease in Down Syndrome. J. Alzheimer\u2019s Dis. 91(3), 1215\u20131227 (2023).","journal-title":"J. Alzheimer's Dis."},{"issue":"174","key":"61962_CR44","first-page":"184","volume":"14","author":"WM Jolink","year":"2023","unstructured":"Jolink, W. M. et al. Histopathology of cerebral microinfarcts and microbleeds in spontaneous intracerebral hemorrhage. Transl. Stroke Res. 14(174), 184 (2023).","journal-title":"Transl. Stroke Res."},{"key":"61962_CR45","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.114.001140","author":"JM Wardlaw","year":"2015","unstructured":"Wardlaw, J. M., Valdes Hernandez, M. C. & Munoz-Maniega, S. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J. Am. Heart Assoc. https:\/\/doi.org\/10.1161\/jaha.114.001140 (2015).","journal-title":"J. Am. Heart Assoc."},{"key":"61962_CR46","doi-asserted-by":"publisher","unstructured":"Lao, P. et al. White matter regions with low microstructure in young adults are associated with white matter hyperintensities in late life. bioRxiv, 517763, doi:https:\/\/doi.org\/10.1101\/517763 (2019).","DOI":"10.1101\/517763"},{"issue":"704","key":"61962_CR47","first-page":"715","volume":"17","author":"D Wilcock","year":"2021","unstructured":"Wilcock, D. et al. MarkVCID cerebral small vessel consortium: I Enrollment, clinical, fluid protocols. Alzheimer\u2019s Dement. 17(704), 715 (2021).","journal-title":"Alzheimer's Dement."},{"key":"61962_CR48","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1161\/STROKEAHA.123.044172","volume":"55","author":"KE Foley","year":"2024","unstructured":"Foley, K. E. & Wilcock, D. M. Soluble biomarkers of cerebrovascular pathologie. Stroke 55, 801\u2013811 (2024).","journal-title":"Stroke"},{"key":"61962_CR49","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N. Engl. J. Med. 367, 795\u2013804. https:\/\/doi.org\/10.1056\/NEJMoa1202753 (2012).","journal-title":"N. Engl. J. Med."},{"key":"61962_CR50","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/s41591-023-02476-4","volume":"29","author":"EC Johnson","year":"1988","unstructured":"Johnson, E. C. et al. 2023 Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer\u2019s disease. Nat. Med. 29, 1979 (1988).","journal-title":"Nat. Med."},{"key":"61962_CR51","doi-asserted-by":"publisher","first-page":"e13097","DOI":"10.1111\/bpa.13097","volume":"32","author":"JL Littau","year":"2022","unstructured":"Littau, J. L. et al. Evidence of beta amyloid independent small vessel disease in familial Alzheimer\u2019s disease. Brain Pathol. 32, e13097 (2022).","journal-title":"Brain Pathol."},{"key":"61962_CR52","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jalz.2017.03.007","volume":"13","author":"M Carmona-Iragui","year":"2017","unstructured":"Carmona-Iragui, M. et al. Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 13, 1251\u20131260 (2017).","journal-title":"Alzheimer's Dement."},{"key":"61962_CR53","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1474-4422(16)30229-0","volume":"15","author":"M Tang","year":"2016","unstructured":"Tang, M. et al. Neurological manifestations of autosomal dominant familial Alzheimer\u2019s disease: A comparison of the published literature with the dominantly inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol. 15, 1317\u20131325 (2016).","journal-title":"Lancet Neurol."},{"key":"61962_CR54","doi-asserted-by":"publisher","first-page":"e1632","DOI":"10.1212\/WNL.0000000000011542","volume":"96","author":"N Joseph-Mathurin","year":"2021","unstructured":"Joseph-Mathurin, N. et al. Longitudinal accumulation of cerebral microhemorrhages in dominantly inherited Alzheimer disease. Neurology 96, e1632\u2013e1645 (2021).","journal-title":"Neurology"},{"key":"61962_CR55","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jamaneurol.2023.3618","volume":"80","author":"Z Shirzadi","year":"2023","unstructured":"Shirzadi, Z. et al. Etiology of white matter hyperintensities in autosomal dominant and sporadic Alzheimer disease. JAMA Neurol. 80, 1353\u20131363 (2023).","journal-title":"JAMA Neurol."},{"issue":"104","key":"61962_CR56","first-page":"114","volume":"95","author":"S Ingala","year":"2020","unstructured":"Ingala, S. et al. The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle-and old-aged individuals. Neurobiol. Aging 95(104), 114 (2020).","journal-title":"Neurobiol. Aging"},{"issue":"1699","key":"61962_CR57","first-page":"1701","volume":"63","author":"D Van Den Heuvel","year":"2004","unstructured":"Van Den Heuvel, D. et al. Different progression rates for deep white matter hyperintensities in elderly men and women. Neurology 63(1699), 1701 (2004).","journal-title":"Neurology"},{"key":"61962_CR58","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1097\/HJH.0000000000000686","volume":"33","author":"J Gutierrez","year":"2015","unstructured":"Gutierrez, J. et al. Pulsatile and steady components of blood pressure and subclinical cerebrovascular disease: The Northern Manhattan Study. J. Hypertens. 33, 2115 (2015).","journal-title":"J. Hypertens."},{"key":"61962_CR59","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1212\/WNL.0000000000003746","volume":"88","author":"A Charidimou","year":"2017","unstructured":"Charidimou, A. et al. MRI-visible perivascular spaces in cerebral amyloid angiopathy and hypertensive arteriopathy. Neurology 88, 1157\u20131164 (2017).","journal-title":"Neurology"},{"issue":"1","key":"61962_CR60","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/sleepadvances\/zpac013","volume":"3","author":"P Lao","year":"2022","unstructured":"Lao, P. et al. Obstructive sleep apnea, cerebrovascular disease, and amyloid in older adults with Down syndrome across the Alzheimer\u2019s continuum. Sleep Adv. 3(1), 130 (2022).","journal-title":"Sleep Adv."},{"key":"61962_CR61","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neurobiolaging.2020.04.018","volume":"93","author":"KA Cody","year":"2020","unstructured":"Cody, K. A. et al. Association of sleep with cognition and beta amyloid accumulation in adults with Down syndrome. Neurobiol. Aging 93, 44\u201351 (2020).","journal-title":"Neurobiol. Aging"},{"key":"61962_CR62","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/jar.12369","volume":"30","author":"AV Kenshole","year":"2017","unstructured":"Kenshole, A. V., Gallichan, D., Pahl, S. & Clibbens, J. Lifestyle factors and Alzheimer\u2019s disease in people with Down syndrome. J. Appl. Res. Intell. Disabil. 30, 58\u201366 (2017).","journal-title":"J. Appl. Res. Intell. Disabil."},{"key":"61962_CR63","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1352\/1934-9556-55.2.97","volume":"55","author":"I Mihaila","year":"2017","unstructured":"Mihaila, I. et al. Leisure activity and caregiver involvement in middle-aged and older adults with Down syndrome. Intell. Dev. Disabil. 55, 97\u2013109 (2017).","journal-title":"Intell. Dev. Disabil."},{"key":"61962_CR64","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/dneu.22677","volume":"79","author":"I Mihaila","year":"2019","unstructured":"Mihaila, I. et al. Leisure activity brain \u03b2-amyloid, and episodic memory in adults with Down Syndrome. Dev. Neurobiol. 79, 738\u2013749 (2019).","journal-title":"Dev. Neurobiol."},{"key":"61962_CR65","volume":"12","author":"BL Handen","year":"2020","unstructured":"Handen, B. L. et al. The Alzheimer\u2019s biomarker consortium-Down syndrome: Rationale and methodology. Alzheimer\u2019s Dement.: Diagn. Assess. Dis. Monit. 12, e12065 (2020).","journal-title":"Alzheimer's Dement.: Diagn. Assess. Dis. Monit."},{"key":"61962_CR66","volume":"12","author":"SJ Krinsky-McHale","year":"2020","unstructured":"Krinsky-McHale, S. J. et al. Promising outcome measures of early Alzheimer\u2019s dementia in adults with Down syndrome. Alzheimer\u2019s Dement.: Diagn. Assess. Dis. Monit. 12, e12044 (2020).","journal-title":"Alzheimer's Dement.: Diagn. Assess. Dis. Monit."},{"key":"61962_CR67","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3174\/ajnr.A5129","volume":"38","author":"J Gutierrez","year":"2017","unstructured":"Gutierrez, J. et al. Brain perivascular spaces as biomarkers of vascular risk: Results from the northern manhattan study. Am. J. Neuroradiol. 38, 862\u2013867 (2017).","journal-title":"Am. J. Neuroradiol."},{"key":"61962_CR68","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.3174\/ajnr.A3498","volume":"34","author":"J Gutierrez","year":"2013","unstructured":"Gutierrez, J., Rundek, T., Ekind, M., Sacco, R. L. & Wright, C. B. Perivascular spaces are associated with atherosclerosis: An insight from the Northern Manhattan study. Am. J. Neuroradiol. 34, 1711\u20131716 (2013).","journal-title":"Am. J. Neuroradiol."},{"issue":"1","key":"61962_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk, W. E. et al. The Centiloid Project standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 11(1), 1\u201315. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003 (2015).","journal-title":"Alzheimers Dement."},{"key":"61962_CR70","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.dadm.2018.03.006","volume":"10","author":"DL Tudorascu","year":"2018","unstructured":"Tudorascu, D. L. et al. The use of Centiloids for applying [(11)C]PiB classification cutoffs across region-of-interest delineation methods. Alzheimer\u2019s Dement. 10, 332\u2013339. https:\/\/doi.org\/10.1016\/j.dadm.2018.03.006 (2018).","journal-title":"Alzheimer's Dement."},{"issue":"2","key":"61962_CR71","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2307\/2335690","volume":"64","author":"RB Davies","year":"2002","unstructured":"Davies, R. B. Hypothesis testing when a nuisance parameter is present only under the alternative: Linear model case. Biometrika 64(2), 247\u2013254 (2002).","journal-title":"Biometrika"},{"key":"61962_CR72","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2967\/jnumed.121.262464","volume":"63","author":"F Orlhac","year":"2022","unstructured":"Orlhac, F. et al. A guide to ComBat harmonization of imaging biomarkers in multicenter studies. J. Nucl. Med. 63, 172\u2013179 (2022).","journal-title":"J. Nucl. Med."},{"key":"61962_CR73","first-page":"63","volume":"12","author":"RL Koscik","year":"2020","unstructured":"Koscik, R. L. et al. Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimer\u2019s Dement.: Diagn. Assess. Dis. Monit. 12, 63\u201372 (2020).","journal-title":"Alzheimer's Dement.: Diagn. Assess. Dis. Monit."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61962-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61962-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61962-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T12:05:31Z","timestamp":1716984331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-61962-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["61962"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-61962-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael A. Yassa has received consulting fees from Eisai Cognito Therapeutics, LLC, CuraSen Therapeutics, Inc, and Enthorin Therapeutics, LLC. Adam Brickman receives compensation for consultation to Cognition Therapeutics and Cognito Therapeutics and for his role on the Scientific Advisory Board of CogState. He is an inventor a patent for white matter hyperintensity quantification (US Patent US9867566B2) and serves on a Data Safety Monitoring Board for University of Illinois, Urbana-Champaign. All other authors do not have competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12334"}}